reconstitut
fresh
whole
blood
improv
clinic
outcom
compar
store
compon
blood
therapi
neonat
undergo
cardiopulmonari
bypass
cardiac
surgeri
random
control
trial
object
studi
compar
effect
reconstitut
fresh
whole
blood
standard
blood
compon
therapi
neonat
undergo
cardiac
surgeri
method
patient
less
month
age
random
receiv
either
reconstitut
fresh
whole
blood
n
standard
blood
compon
therapi
n
prime
bypass
circuit
transfus
hour
cardiopulmonari
bypass
primari
outcom
chest
tube
drainag
secondari
outcom
includ
transfus
need
inotrop
score
ventil
time
hospit
length
stay
result
patient
receiv
reconstitut
fresh
whole
blood
significantli
less
postop
chest
tube
volum
loss
per
kilogram
bodi
weight
mlkg
vs
mlkg
p
standard
blood
compon
therapi
associ
higher
inotrop
score
vs
p
longer
ventil
time
hour
vs
hour
p
well
longer
hospit
stay
day
vs
day
p
patient
receiv
reconstitut
fresh
whole
blood
differ
factor
associ
use
reconstitut
fresh
whole
blood
lower
platelet
count
minut
end
cardiopulmonari
bypass
older
age
cell
use
prime
throughout
bypass
exposur
higher
number
allogen
donor
found
independ
predictor
poor
clinic
outcom
conclus
reconstitut
fresh
whole
blood
use
prime
throughout
cardiopulmonari
bypass
transfus
requir
within
first
hour
postop
result
reduc
chest
tube
volum
loss
improv
clinic
outcom
neonat
patient
undergo
cardiac
surgeri
earn
cme
credit
http
cmectsnetjournalsorg
morbid
mortal
neonat
heart
surgeri
repair
congenit
heart
diseas
dramat
improv
past
decad
howev
remain
higher
older
children
adult
partli
associ
exagger
disrupt
coagul
stimul
inflammatori
respons
neonat
undergo
cardiopulmonari
bypass
cpb
congenit
heart
diseas
disturb
coagul
lead
postop
bleed
neonat
result
interact
mani
mechan
includ
factor
hemostat
system
immatur
hemodilut
system
inflamm
prolong
bypass
time
use
deep
hypotherm
circulatori
arrest
dhca
increas
bleed
allogen
blood
transfus
requir
shown
vari
invers
age
size
infant
requir
cardiac
surgeri
transfus
allogen
blood
product
associ
number
advers
effect
infecti
agent
transmiss
develop
postop
infect
transfus
reaction
previou
studi
use
fresh
whole
blood
either
prime
cpb
circuit
meet
postop
transfus
requir
report
conflict
result
studi
compar
use
reconstitut
fresh
whole
blood
rfwb
versu
standard
blood
compon
therapi
prime
cpb
circuit
replac
postop
blood
loss
within
first
hour
surgeri
sought
determin
whether
use
rfwb
cpb
first
hour
postop
would
improv
clinic
outcom
compar
standard
blood
compon
therapi
initi
creat
sever
acut
respiratori
syndrom
sar
epidem
march
well
difficulti
coordin
oper
patient
consent
blood
acquisit
explain
lengthier
enrol
period
necessari
surgeon
blind
patient
group
random
wherea
perfus
anesthesia
cardiac
critic
care
unit
cccu
staff
unblind
institut
research
ethic
board
approv
grant
hospit
sick
children
toronto
ontario
canada
written
inform
consent
obtain
legal
guardian
patient
enrol
studi
random
independ
safeti
committe
oversaw
studi
member
clinic
respons
studi
subject
tie
studi
investig
sixtyfour
patient
met
inclus
criteria
less
month
age
schedul
elect
cardiac
surgeri
requir
cpb
exclus
criteria
includ
emerg
surgeri
patient
known
preexist
coagulopathi
subject
random
block
patient
receiv
either
rfwb
prime
cpb
circuit
transfus
requir
hour
postop
treatment
group
n
standard
blood
compon
therapi
control
group
n
requir
sampl
size
calcul
basi
previou
studi
fresh
whole
blood
versu
compon
therapi
calcul
sampl
size
patient
would
detect
reduct
chest
tube
volum
loss
alpha
power
blood
product
use
studi
group
collect
random
volunt
donor
process
accord
canadian
blood
servic
cb
standard
oper
procedur
routin
test
infecti
agent
perform
donat
blood
issu
cb
studi
group
cb
requir
donor
blood
separ
compon
red
blood
cell
random
donor
platelet
fresh
frozen
plasma
immedi
collect
leukocyt
reduc
filtrat
storag
donor
blood
collect
bag
contain
anticoagul
solut
citrat
phosphat
doubl
dextros
nutricel
haemonet
braintre
mass
preserv
ad
pack
red
blood
cell
prbc
compon
store
c
c
subsequ
remov
prbc
releas
blood
transfus
laboratori
hospit
sick
children
per
standard
hospit
protocol
neonat
patient
plasma
frozen
within
hour
donat
store
c
less
platelet
continu
agit
storag
c
c
separ
plateletrich
plasma
hard
spin
centrifug
patient
random
treatment
arm
cb
notifi
design
unit
abocompat
singl
random
donor
blood
two
separ
donor
releas
hospit
blood
transfus
laboratori
morn
oper
one
rfwb
unit
prepar
reconstitut
compon
singl
donor
process
previous
describ
second
unit
rfwb
prepar
releas
requir
rfwb
unit
collect
day
morn
oper
patient
control
group
receiv
abocompat
store
blood
compon
per
standard
hospit
protocol
prbc
platelet
irradi
morn
oper
either
reconstitut
releas
individu
compon
depend
random
platelet
compon
use
control
group
random
singl
donor
platelet
collect
day
median
day
surgeri
either
origin
state
concentr
discret
attend
anesthesiologist
anesthesia
induc
sodium
thiopenton
mgkg
fentanyl
mgkg
muscl
relax
pancuronium
mgkg
appropriates
endotrach
tube
place
anesthesia
maintain
isofluran
air
oxygen
supplement
dose
fentanyl
clinic
indic
patient
given
aprotinin
trasylol
bayer
ag
leverkusen
germani
cpb
dose
kiukg
test
dose
kiukg
cefazolin
ancef
glaxosmithklin
london
unit
kingdom
mgkg
given
wound
prophylaxi
patient
undergo
dhca
given
methylprednisolon
mgkg
anticoagul
initi
dose
iu
heparin
sulfat
per
kilogram
bodi
weight
target
activ
clot
time
act
second
institut
cpb
addit
heparin
given
cpb
act
less
second
protamin
sulfat
given
ratio
revers
anticoagul
base
initi
heparin
dose
addit
dose
given
base
subsequ
act
cpb
circuit
prime
solut
compos
follow
electrolyt
solut
plasmalyt
baxter
healthcar
deerfield
ill
mannitol
gkg
steril
water
ml
albumin
ml
random
blood
product
either
rfwb
prbc
compon
ad
achiev
cpb
hematocrit
valu
cefazolin
ml
prime
volum
calcium
chlorid
heparin
sulfat
iuml
prime
also
ad
total
volum
approxim
ml
aprotinin
ad
prime
dose
ml
prime
volum
test
dose
safe
given
ultrafiltr
use
cpb
remov
excess
fluid
ad
throughout
surgic
procedur
blood
flow
maintain
cpb
mlkg
bodi
weight
patient
undergo
dhca
activ
cool
rectal
temperatur
c
phstat
blood
ga
manag
use
cool
patient
allow
passiv
cool
c
bodi
temperatur
alphastat
blood
ga
manag
use
throughout
myocardi
protect
achiev
blood
cardioplegia
use
blood
crystalloid
mixtur
ratio
addit
mannitol
given
aortic
crossclamp
remov
dose
mgkg
patient
receiv
blood
product
either
rfwb
prbc
maintain
hematocrit
valu
cpb
reach
target
hematocrit
valu
acyanot
patient
cyanot
patient
wean
cpb
patient
random
receiv
compon
blood
therapi
receiv
unit
fresh
frozen
plasma
heparin
sulfat
iuml
ad
aortic
crossclamp
remov
patient
underw
modifi
ultrafiltr
cpb
cpb
control
patient
given
compon
volum
replac
accord
follow
transfus
guidelin
prbc
hematocrit
valu
less
acyanot
patient
cyanot
patient
platelet
kg
platelet
count
less
cryoprecipit
fibrinogen
level
less
gl
addit
fresh
frozen
plasma
ongo
bleed
patient
random
treatment
group
receiv
rfwb
hemostasi
volum
replac
requir
avail
unit
use
standard
blood
compon
therapi
use
accord
aforement
transfus
guidelin
arteri
blood
sampl
obtain
patient
placement
arteri
line
minut
start
cpb
aortic
crossclamp
remov
end
cpb
protamin
hour
cccu
addit
blood
sampl
taken
everi
hour
cccu
result
use
guid
transfus
protocol
previous
describ
blood
sampl
analyz
complet
blood
count
fibrinogen
biochemistri
interleukin
tumor
necrosi
factor
tnfa
level
measur
induct
anesthesia
hour
arriv
cccu
tnfa
level
measur
immunometr
assay
immulit
analyz
eurodpc
llanberi
unit
kingdom
surgeon
gave
subject
assess
intraop
bleed
grade
mild
moder
sever
leav
oper
room
chest
tube
drainag
hematocrit
valu
within
first
hour
cccu
admiss
measur
blood
transfus
cpb
hour
postop
tabul
total
volum
type
number
blood
product
unit
transfus
transfus
guidelin
use
cccu
use
immedi
cpb
inotrop
support
score
calcul
hour
arriv
cccu
mean
follow
formula
use
drug
dosag
express
microgram
per
kilogram
per
minut
dopamin
dobutamin
epinephrin
milrinon
total
ventil
hour
cccu
hospit
length
stay
also
compar
data
describ
frequenc
median
rang
mean
standard
deviat
appropri
baselin
characterist
outcom
compar
fisher
exact
test
c
test
kruskalw
analysi
varianc
student
test
appropri
account
repeat
measur
multipl
comparison
differ
group
serial
measur
laboratori
inflammatori
marker
variabl
test
multivari
mix
linear
regress
model
use
compound
symmetri
covari
structur
compound
symmetri
covari
structur
calcul
account
correl
multipl
observ
patient
multivari
regress
model
creat
use
maximum
likelihood
estim
determin
independ
effect
age
blood
cell
prime
allogen
donor
exposur
platelet
count
medic
outcom
interest
account
correl
variabl
given
skew
distribut
inflammatori
marker
variabl
distribut
normal
logarithm
transform
analys
perform
sa
statist
softwar
version
sa
institut
inc
cari
nc
experiment
group
similar
term
demograph
intraop
characterist
tabl
norwood
surgeri
requir
steroid
found
affect
relationship
blood
transfus
surgic
outcom
even
though
unevenli
distribut
group
patient
surviv
cccu
discharg
one
patient
rfwb
group
die
hospit
discharg
day
surgeri
result
studi
design
compon
group
significantli
higher
mean
blood
donor
unit
exposur
ae
unit
rfwb
group
ae
unit
cpb
postop
blood
transfus
requir
includ
p
blood
cell
use
prime
significantli
older
compon
group
ae
day
rfwb
group
day
p
signific
differ
two
group
median
total
volum
transfus
within
studi
period
tabl
signific
differ
measur
hematocrit
valu
chest
tube
drainag
two
group
bleed
describ
surgeon
frequent
moder
sever
compon
group
rfwb
group
p
statist
signific
correl
surgeon
assess
bleed
postop
chest
tube
volum
loss
p
rfwb
group
significantli
lower
median
inotrop
score
hour
cccu
compon
group
p
tabl
proport
patient
undergo
norwood
oper
somewhat
unequ
group
subanalysi
includ
patient
undergo
norwood
oper
perform
tabl
found
relationship
rfwb
improv
postop
outcom
attribut
slightli
higher
number
norwood
patient
control
group
versu
rfwb
group
regress
model
correct
use
corticosteroid
deep
hypothermia
staff
surgeon
alter
differ
improv
clinic
outcom
use
rfwb
induct
patient
similar
valu
arteri
blood
gase
fibrinogen
electrolyt
magnesium
calcium
glucos
lactat
hematolog
indic
figur
lactat
potassium
calcium
level
significantli
higher
cpb
circuit
prime
compon
group
p
although
statist
differ
observ
sporad
time
point
sodium
calcium
magnesium
glucos
bicarbon
clinic
relev
differ
observ
group
signific
differ
group
time
colloid
osmot
pressur
base
deficit
ph
white
cell
count
act
significantli
higher
compon
group
time
aortic
crossclamp
remov
p
fibrinogen
level
significantli
higher
compon
group
protamin
p
remain
similar
across
group
thereaft
serum
potassium
level
significantli
higher
compon
group
cpb
circuit
prime
p
minut
cpb
p
time
aortic
crossclamp
remov
p
end
cpb
p
hematocrit
level
significantli
higher
compon
group
minut
cpb
p
end
cpb
p
postprotamin
period
p
similar
find
hemoglobin
data
shown
platelet
count
significantli
lower
compon
group
minut
cpb
p
end
cpb
p
induct
valu
marker
system
inflamm
tnfa
similar
group
p
p
tnfa
signific
increas
marker
measur
hour
cpb
hour
cbp
significantli
greater
increas
seen
compon
group
compar
rfwb
group
vs
rfwb
hour
confid
interv
p
vs
rfwb
hour
confid
interv
p
tnfa
use
rfwb
describ
method
section
affect
import
paramet
blood
transfus
age
infus
cell
number
allogen
donor
exposur
platelet
count
bypass
effect
rfwb
like
multifactori
natur
analys
perform
quantifi
rel
effect
compon
univari
analysi
chest
tube
loss
hour
cccu
inotrop
score
hour
durat
ventil
hospit
stay
found
significantli
associ
age
blood
product
given
prime
throughout
cpb
exposur
allogen
donor
platelet
count
end
bypass
multivari
analysi
tabl
lower
platelet
count
end
bypass
older
age
blood
product
given
prime
throughout
cpb
exposur
higher
number
allogen
donor
found
independ
predictor
higher
chest
tube
loss
hour
longer
durat
ventil
lower
platelet
count
end
bypass
exposur
higher
number
allogen
donor
independ
predictor
higher
inotrop
score
hour
lower
platelet
count
end
bypass
older
age
blood
cell
given
prime
throughout
bypass
found
independ
predictor
longer
durat
hospit
stay
interest
relationship
observ
platelet
count
end
cpb
clinic
outcom
replic
platelet
count
minut
cpb
neonat
undergo
cpb
open
cardiac
surgeri
gener
oblig
receiv
blood
transfus
owe
periop
bleed
exacerb
preexist
coagul
defect
use
cpb
risk
blood
transfus
morbid
associ
postop
bleed
effort
made
reduc
allogen
donor
exposur
use
fresh
whole
blood
shown
reduc
postop
bleed
infant
patient
howev
recent
transfus
medicin
standard
support
widespread
usag
prepar
rfwb
product
use
studi
follow
current
cb
hospit
transfus
laboratori
standard
oper
procedur
includ
durat
blood
storag
reconstitut
product
use
studi
may
superior
tradit
fresh
whole
blood
owe
prestorag
leukocyt
deplet
storag
platelet
room
temperatur
prestorag
leukocyt
deplet
standard
blood
compon
prepar
canada
current
filter
reduc
number
leukocyt
present
blood
log
valu
believ
alloimmun
suppress
occur
platelet
store
room
temperatur
exhibit
better
hemostat
properti
store
cold
temperatur
routin
tradit
whole
blood
storag
neonat
receiv
rfwb
significantli
improv
clinic
outcom
includ
less
postop
chest
tube
volum
loss
first
hour
cccu
significantli
lower
inotrop
score
decreas
ventil
time
reduc
hospit
length
stay
demonstr
studi
three
factor
affect
use
rfwb
independ
contribut
improv
outcom
higher
platelet
count
minut
end
cpb
reduc
number
allogen
donor
exposur
younger
age
blood
product
patient
rfwb
group
expos
significantli
reduc
number
donor
part
result
studi
design
coupl
reduct
postop
chest
tube
volum
loss
significantli
reduc
inotrop
score
ventil
time
hospit
rfwb
patient
group
shown
independ
associ
lower
number
donor
exposur
higher
platelet
count
minut
end
cpb
associ
significantli
reduc
chest
tube
volum
loss
support
investig
therefor
result
indic
import
use
rfwb
prime
cpb
circuit
well
throughout
cpb
median
age
prbc
compon
use
control
group
day
median
age
platelet
day
current
standard
cb
increas
length
storag
prbc
associ
increas
risk
postop
pneumonia
increas
durat
stay
cardiac
surgic
popul
furthermor
transfus
platelet
store
less
hour
shown
associ
larger
increas
posttransfus
platelet
increment
longer
platelet
transfus
interv
differ
age
blood
use
two
studi
group
contribut
improv
clinic
outcom
rfwb
group
interestingli
studi
observ
marker
inflamm
measur
tnfa
experienc
significantli
greater
increas
compon
group
compar
rfwb
group
previou
studi
shown
figur
serial
laboratori
measur
laboratori
variabl
show
signific
interact
intervent
assign
time
period
shown
data
present
least
squar
mean
error
bar
repres
standard
error
mean
deriv
mix
linear
regress
analysi
adjust
repeat
measur
signific
p
valu
report
multivari
analysi
p
act
activ
clot
time
cccu
cardiac
critic
care
unit
cpb
cardiopulmonari
bypass
level
measur
cpb
children
marker
earli
postop
morbid
result
studi
contradict
previou
random
control
trial
fresh
whole
blood
versu
compon
therapi
mou
colleagu
found
differ
postop
outcom
experiment
group
secondari
clinic
measur
show
advantag
compon
therapi
major
issu
studi
design
consid
contrast
studi
first
use
fresh
whole
blood
prime
bypass
circuit
use
compon
therapi
transfus
requir
might
obscur
effect
fresh
whole
blood
second
use
blood
arm
studi
leukodeplet
could
offset
gain
made
use
fresh
whole
blood
final
morbid
mortal
rate
postop
period
might
confound
result
overshadow
improv
made
use
fresh
whole
blood
furthermor
anoth
studi
manno
colleagu
also
found
use
fresh
whole
blood
prime
periop
postop
requir
associ
improv
clinic
outcom
thu
support
result
current
studi
studi
put
forward
clinic
advantag
use
fresh
whole
blood
context
neonat
cardiac
surgeri
logist
issu
may
prevent
replic
strategi
routin
context
nonetheless
mani
featur
fresh
reconstitut
whole
blood
strategi
show
independ
associ
improv
outcom
fresher
blood
smaller
number
exposur
higher
platelet
count
bypass
mani
featur
obtain
modifi
compon
therapi
protocol
even
singl
donor
whole
blood
unavail
singl
donor
rfwb
practic
altern
strategi
may
includ
use
reconstitut
fresh
compon
multipl
donor
may
replic
effect
rfwb
without
challeng
obtain
singl
donor
product
addit
fresh
platelet
prime
achiev
higher
platelet
count
initi
bypass
throughout
surgeri
found
import
element
effect
rfwb
assumpt
yet
support
research
futur
studi
could
focu
methodolog
emul
effect
rfwb
use
differ
techniqu
rfwb
avail
studi
must
view
light
limit
enrol
period
extend
owe
logist
issu
meant
limit
proport
elig
neonat
could
enrol
studi
howev
date
surgeri
found
associ
clinic
outcom
age
red
cell
platelet
compon
therapi
group
older
use
center
within
accept
cb
standard
oper
procedur
assess
blood
loss
postop
period
took
account
drainag
chest
tube
account
potenti
blood
collect
pleural
caviti
blood
accumul
mediastinum
patient
open
chest
intens
care
unit
despit
fact
use
chest
tube
volum
loss
surrog
postop
bleed
could
underestim
total
blood
loss
reason
believ
differ
would
unevenli
distribut
experiment
group
final
previou
surgic
studi
also
use
chest
tube
volum
loss
surrog
postop
bleed
pediatr
patient
undergo
open
cardiac
surgeri
conclus
studi
advoc
use
singl
donor
rfwb
prime
bypass
circuit
throughout
cpb
transfus
requir
first
hour
surgeri
techniqu
associ
signific
reduct
chest
tube
volum
loss
neonat
patient
undergo
cpb
cardiac
surgeri
furthermor
patient
receiv
rfwb
significantli
better
clinic
outcom
includ
decreas
need
inotrop
support
reduc
ventil
time
shorter
hospit
length
stay
light
data
adopt
modifi
practic
use
platelet
prime
fresher
blood
compon
limit
donor
exposur
could
highli
benefici
